Core Viewpoint - The article highlights the journey of Sun Xiulian, a former doctor turned pharmaceutical entrepreneur, who founded Yiming Bio to focus on the production and early-stage development of cell and gene therapy (CGT) drugs, addressing the challenges in the CGT industry and aiming to improve drug accessibility for patients [3][4][6]. Group 1: Company Overview - Yiming Bio provides one-stop CGT CDMO (Contract Development and Manufacturing Organization) services, assisting innovative drug companies in developing CGT drugs from the lab to clinical trials [4][27]. - The company has collaborated with over a hundred pharmaceutical firms, completing more than 300 batches of various innovative drug productions that meet international GMP standards [27]. Group 2: Industry Challenges - The success rate for new drug projects entering IND (Investigational New Drug) approval is approximately 1 in 10, with CGT projects facing even lower success rates due to complex manufacturing processes and high costs [3][8]. - The average price of CAR-T therapy exceeds 1 million, with production costs around 200,000, making affordability a significant issue for patients [15]. Group 3: Technological Innovations - Yiming Bio has developed methods to significantly reduce the manufacturing costs of CGT drugs, achieving an 80% reduction in the cost of plasmid production through process optimization [16]. - The company can produce LV (Lentivirus) raw materials for CAR-T therapy at a cost of around 100 USD per dose, which is 100 times lower than traditional methods [18]. Group 4: Market Positioning - The CGT industry has a high outsourcing penetration rate of over 65%, compared to 35% for traditional biopharmaceuticals, indicating a strong demand for CDMO services in this sector [9]. - Yiming Bio is strategically focusing on cell therapy, particularly in oncology, due to its broader market potential compared to gene therapy, which faces challenges in commercialization [28]. Group 5: Future Plans - The company aims to expand its global footprint, establishing bases in both China and the United States to cater to the growing demand for CGT products [29][31]. - Yiming Bio's vision is to enhance the accessibility of advanced therapy medicinal products (ATMP) by improving manufacturing efficiency, thereby making innovative drugs more affordable for patients [32].